文献速递颈动脉与弓上血管

经颈动脉血运重建与颈动脉支架置入联合远端栓塞保护的脑过度灌注综合征风险比较

Cerebral Hyperperfusion Syndrome Risk Comparison between Transcarotid Artery Revascularization and Carotid Artery Stenting with Distal Embolic Protection.
PubMed 文献 · Ann Vasc Surg · 2025-01-27

基于血管质量倡议数据库2016至2023年数据,纳入69480例接受经颈动脉血运重建(TCAR)或颈动脉支架置入联合远端栓塞保护(CAS+DEP)的患者。TCAR组术后脑过度灌注综合征(CHS)发生率低于CAS+DEP组(0.53% vs 1.1%,P<0.001)。在症状性颈动脉狭窄患者中,TCAR与CHS风险降低相关(aOR 0.52,95%CI 0.40-0.68,P<0.001);发生CHS者中,TCAR组院内死亡和30天死亡更低。

要点

  • TCAR组术后CHS发生率为0.53%,低于CAS+DEP组的1.1%(P<0.001)。
  • 症状性狭窄患者中,TCAR与CHS风险降低相关(aOR 0.52,95%CI 0.40-0.68)。
  • 发生CHS者中,TCAR组院内死亡(aOR 0.51)和30天死亡(aOR 0.46)均低于CAS+DEP组。

核心结论

  • 在症状性颈动脉狭窄患者中,TCAR与CAS+DEP相比CHS风险更低。
  • 发生CHS的患者中,TCAR组CHS程度更轻,且院内死亡和30天死亡率均低于CAS+DEP组。

研究设计与样本

  • 回顾性队列研究,数据来自血管质量倡议数据库2016至2023年。
  • 共纳入69480例患者,其中TCAR占57.47%,CAS+DEP占42.53%。
  • 排除无栓塞保护装置者及颈动脉夹层、创伤或纤维肌性发育不良患者。
  • 患者按无症状与症状性颈动脉狭窄分层,并进一步按血运重建紧迫性分组。

主要发现

  • TCAR组术后CHS发生率低于CAS+DEP组(0.53% vs 1.1%,P<0.001)。
  • 多因素分析中,TCAR与CHS风险降低相关(P<0.001)。
  • 无症状患者中,血运重建方式对CHS发生无显著影响(P=0.610)。
  • 症状性患者中,TCAR与CHS风险降低约2倍相关(aOR 0.52,95%CI 0.40-0.68,P<0.001),择期(P=0.003)和紧急/急诊(P<0.001)病例中均如此。
  • 发生CHS者中,TCAR组院内死亡(aOR 0.51,95%CI 0.27-0.94,P=0.031)和30天死亡(aOR 0.46,95%CI 0.26-0.80,P=0.006)均低于CAS+DEP组。

关键数值与推荐

  • TCAR组CHS发生率0.53% vs CAS+DEP组1.1%(P<0.001)。
  • 症状性患者中TCAR vs CAS+DEP的CHS风险aOR 0.52(95%CI 0.40-0.68,P<0.001)。
  • CHS患者中TCAR vs CAS+DEP的院内死亡aOR 0.51(95%CI 0.27-0.94,P=0.031),30天死亡aOR 0.46(95%CI 0.26-0.80,P=0.006)。
  • CHS患者中TCAR组住院时间更短(aOR 0.58,95%CI 0.36-0.92,P=0.022),严重CHS(癫痫发作和颅内出血)发生率更低(aOR 0.51,95%CI 0.29-0.89,P=0.019)。
  • CAS+DEP组中入院时严重卒中(改良Rankin量表3-5分)者发生严重CHS(P=0.014)。

临床怎么用

  • 原文未据此给出推荐。
  • 在症状性颈动脉狭窄患者中,TCAR与CAS+DEP相比CHS风险更低。
  • 发生CHS的患者中,TCAR组CHS程度更轻,院内和30天死亡率更低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cerebral hyperperfusion syndrome (CHS) is a rare but serious complication after carotid artery revascularization. This study aims to determine the impact of carotid artery stenting (CAS) modality on the incidence, severity, and overall outcomes of CHS after carotid revascularization. METHODS: Data from patients who underwent CAS with either distal embolic protection (CAS + DEP) or transcarotid artery revascularization (TCAR) were obtained from the Vascular Quality Initiative database through the years 2016-2023. Cases without embolic protection device and patients suffering from carotid dissection, trauma, or fibromuscular dysplasia were excluded from the study. Patients were stratified into asymptomatic and symptomatic carotid stenosis groups and then further reviewed based on the urgency of their revascularization. The primary outcome was the occurrence of CHS after revascularization. A subgroup analysis was then performed, evaluating postprocedural outcomes and severity of CHS. Lastly, patients with CHS were further analyzed according to the severity of their stroke on admission using the Modified Rankin Scale. RESULTS: In this analysis, a total of 69,480 (57.47% TCAR; 42.53% CAS + DEP) patients were included. Postprocedural CHS was lower in the TCAR cohort compared to the CAS + DEP cohort (0.53% vs. 1.1%, P < 0.001). On multivariate analysis, TCAR was associated with lower risk of CHS than CAS + DEP (P < 0.001). When considering only asymptomatic patients, revascularization modality did not significantly affect CHS occurrence (P = 0.610). However, in symptomatic patients, TCAR was associated with 2-fold lower risk of CHS (adjusted odds ratio (aOR): 0.52, 95% confidence interval (CI): 0.40-0.68, P < 0.001), in both elective (P = 0.003), and urgent/emergency cases (P < 0.001). Among patients who developed CHS, those undergoing TCAR had decreased in-hospital mortality (aOR: 0.51, 95% CI: 0.27-0.94, P = 0.031) and at 30 days (aOR: 0.46, 95% CI: 0.26-0.80, P = 0.006). TCAR patients with CHS also had a shorter length of hospitalization (aOR: 0.58, 95% CI: 0.36-0.92, P = 0.022) and suffered less frequently from severe CHS with seizures and intracranial hemorrhage (aOR: 0.51, 95% CI: 0.29-0.89, P = 0.019). Patients undergoing CAS + DEP who were admitted with severe stroke (Modified Rankin Scale 3-5) developed severe CHS (P = 0.014). CONCLUSION: In patients with symptomatic carotid artery stenosis, TCAR is associated with a lower risk of CHS compared to CAS + DEP. Among those who develop CHS, patients who undergo TCAR express a milder form of CHS and have lower in-hospital and 30-day mortality than those treated with CAS + DEP.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Chow CY, Kang N, Kenel-Pierre S, et al. Cerebral Hyperperfusion Syndrome Risk Comparison between Transcarotid Artery Revascularization and Carotid Artery Stenting with Distal Embolic Protection. Ann Vasc Surg. 2025. PMID: 39880283. doi:10.1016/j.avsg.2024.12.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。